Results 41 to 50 of about 24,706 (195)

СONCENTRATION OF ANTI-INFLAMATORY CYTOKINES IN CELL CULTURE SUPERNATANTS IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS

open access: yesМедицинская иммунология, 2019
Juvenile idiopathic arthritis is a chronic inflammatory disease of the joints in children, mainly of autoimmune or auto-inflammatory nature. It is a heterogeneous group, which includes different subtypes of the disease. Different mechanisms may play role
I. M. Krivolapova   +2 more
doaj   +1 more source

Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From a Phase 2a, Multicenter, Randomized, Double‐Blind, Proof‐of‐Concept Study

open access: yesArthritis &Rheumatology, EarlyView.
Objective To assess guselkumab + golimumab combination therapy versus guselkumab monotherapy in participants with active psoriatic arthritis (PsA) and inadequate response to tumor necrosis factor inhibitors (TNFi‐IR). Methods Adults with active TNFi‐IR PsA (three or more tender/swollen joints) were randomized (2:1) to subcutaneous guselkumab (100 mg) +
Jose U. Scher   +12 more
wiley   +1 more source

CLINICAL CASE OF TOCILIZUMAB USE IN A PATIENT WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS

open access: yesПедиатрическая фармакология, 2014
The article presents a case of successful use of a preparation of monoclonal antibodies to interleukin 6 receptors (tocilizumab) at asevere systemic juvenile idiopathic arthritis.
O. L. Lomakina   +4 more
doaj   +1 more source

Ten‐Year Public Expenditure Savings Associated with TNF Inhibitor Biosimilars under Australia's Pharmaceutical Benefits Scheme

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Biologic therapies are a major and growing driver of pharmaceutical expenditure globally, with tumor necrosis factor (TNF) inhibitors among the most widely used and costly biologics. In Australia, these therapies are funded through the Pharmaceutical Benefits Scheme (PBS), where biosimilars offer lower cost alternatives; however, the long‐term public ...
Chin Hang Yiu   +4 more
wiley   +1 more source

Ultrasonic Image Characteristics of Palatine Tonsils in Healthy Children and Analysis of Factors Influencing Image Quality

open access: yesJournal of Clinical Ultrasound, Volume 53, Issue 3, Page 436-444, March/April 2025.
The ultrasound detection rate of the palatine tonsils in children was good. There are characteristic ultrasonic image manifestations. Tonsil ultrasound image quality is affected by individual and local factors. ABSTRACT Objective To explore the ultrasonic image characteristics of palatine tonsils in healthy children and the factors affecting image ...
Ying Cao   +5 more
wiley   +1 more source

Tocilizumab in the treatment of systemic juvenile idiopathic arthritis

open access: yesOpen Access Rheumatology: Research and Reviews, 2012
Miho Murakami,1 Minako Tomiita,2,3 Norihiro Nishimoto11Laboratory of Immune Regulation, Wakayama Medical University, Wakayama, 2Department of Pediatrics, Graduate School of Medicine, Chiba University, Chiba, 3Department of Allergy and Rheumatology, Chiba
Murakami M, Tomiita M, Nishimoto N
doaj  

Temporomandibular joint disorders as the only manifestation of juvenile idiopathic arthritis: a case report

open access: yesEinstein (São Paulo)
Juvenile idiopathic arthritis is a term used to include all chronic childhood arthritis of unknown etiology. It is characterized by chronic inflammation persisting for at least 6 weeks, beginning before 16 years of age.
José Renato Ribeiro Pinto   +5 more
doaj   +1 more source

Imaging of juvenile idiopathic arthritis. Part I: Clinical classifications and radiographs [PDF]

open access: yesJournal of Ultrasonography, 2016
Juvenile idiopathic arthritis is the most common autoimmune systemic disease of the connective tissue affecting individuals at the developmental age. Radiography is the primary modality employed in the diagnostic imaging in order to identify changes ...
Iwona Sudoł-Szopińska   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy